Charles River Laboratories International, Inc. (NYSE:CRL) Receives Consensus Rating of “Moderate Buy” from Analysts

Charles River Laboratories International, Inc. (NYSE:CRL) has received an average rating of “Moderate Buy” from the eighteen brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $195.9286.

A number of brokerages recently weighed in on CRL. TD Cowen reduced their target price on shares of Charles River Laboratories International from $205.00 to $197.00 and set a “buy” rating for the company in a report on Monday, November 10th. Robert W. Baird raised Charles River Laboratories International from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $178.00 to $199.00 in a research note on Thursday, November 6th. Morgan Stanley set a $185.00 target price on Charles River Laboratories International in a report on Monday, December 1st. Barclays upped their target price on Charles River Laboratories International from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Finally, Mizuho lifted their price objective on shares of Charles River Laboratories International from $174.00 to $200.00 and gave the stock a “neutral” rating in a research report on Thursday, December 18th.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Exchange Traded Concepts LLC increased its position in Charles River Laboratories International by 1.3% in the 2nd quarter. Exchange Traded Concepts LLC now owns 5,742 shares of the medical research company’s stock worth $871,000 after buying an additional 76 shares during the period. Hantz Financial Services Inc. increased its position in Charles River Laboratories International by 11.2% during the third quarter. Hantz Financial Services Inc. now owns 793 shares of the medical research company’s stock worth $124,000 after acquiring an additional 80 shares during the period. Advisory Services Network LLC raised its stake in Charles River Laboratories International by 2.6% during the 3rd quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock valued at $505,000 after purchasing an additional 83 shares during the last quarter. Rothschild Investment LLC raised its stake in Charles River Laboratories International by 82.4% during the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 84 shares during the last quarter. Finally, Patriot Financial Group Insurance Agency LLC boosted its holdings in Charles River Laboratories International by 4.2% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 2,120 shares of the medical research company’s stock valued at $332,000 after purchasing an additional 85 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

NYSE:CRL opened at $203.55 on Monday. The company has a quick ratio of 1.10, a current ratio of 1.37 and a debt-to-equity ratio of 0.64. The business’s 50-day moving average price is $182.85 and its 200 day moving average price is $167.67. Charles River Laboratories International has a 52-week low of $91.86 and a 52-week high of $204.47. The firm has a market cap of $10.02 billion, a P/E ratio of -130.48, a PEG ratio of 6.39 and a beta of 1.63.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, beating the consensus estimate of $2.32 by $0.11. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $990.43 million. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The business’s revenue for the quarter was down .5% on a year-over-year basis. During the same quarter last year, the firm posted $2.59 EPS. As a group, sell-side analysts predict that Charles River Laboratories International will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.